Peerschke and colleagues demonstrated that sera from SLE patients could fix complement and induce C1q/C4d deposition on platelets in vitro, measured by a solid phase-based enzyme-linked immunosorbent assay [36]; this complement fixation/activation activity was associated with the presence of IgG aCL and aβ2GPI antibodies in serum samples tested. This evidence concerns the gene ACLY and systemic lupus erythematosus.